Pfizer
NEWS
Pfizer will acquire the Seattle-based antibody-drug conjugate leader in a $43 billion deal expected to close late in 2023 or early 2024.
The FDA has approved Pfizer’s nasal spray, zavegepant, now to be marketed as Zavzpret, for the acute treatment of migraine in adults, the company announced Friday.
Wednesday, the FDA’s VRBPAC agreed that GSK’s respiratory syncytial virus vaccine candidate is safe and effective in older adults.
Seagen and Pfizer are in early-stage talks over a potential acquisition that could exceed $30 billion.
The FDA is expected to cap off February with a trio of verdicts, including one for a heart failure treatment and another potential first approval for a rare, neurodegenerative disease.
The FDA accepted the BLA for and granted Pfizer’s maternal RSV vaccine candidate priority review.
Pfizer and Valneva are dropping approximately half of enrolled participants in the Phase III VALOR study for their Lyme disease vaccine candidate, VLA15.
Pfizer reported full-year 2022 earnings Tuesday and provided 2023 projections far below the previous year’s totals.
Pfizer forecasts stable growth in the coming years, driven by a strong product push to cushion its non-COVID business and exclusivity losses.
JOBS
IN THE PRESS